|Day Low/High||96.42 / 98.67|
|52 Wk Low/High||69.47 / 125.86|
Jim Cramer says that in good markets there are always multiple ways for investors to win.
This downward action in the small biotech sector tends to happen often in the 'dog days' of summer.
This exclusive group of stocks is among the best when it comes to returning cash to shareholders and building wealth over time.
NEW YORK, July 31, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AbbVie Inc.
Blue Chip stocks are the way to go right now. Here are several key names worth considering.
- Reports Second-Quarter Diluted EPS of $1.26 on a GAAP Basis; Adjusted Diluted EPS of $2.00 Reflects Growth of 40.8 Percent
This stock is still going wild after earnings.
U.S. stock futures rise modestly on Friday ahead of data on second-quarter GDP; Amazon's profit in the second quarter tops $2 billion; Intel shares fell despite the chipmaker beating earnings forecasts.
CHICAGO, July 26, 2018 /PRNewswire/ -- Keller Lenkner LLC ("Keller Lenkner") today announced that a class action has been commenced by an institutional investor on behalf of purchasers of AbbVie Inc.
Here are the top healthcare bets ticking all the boxes for analysts.
The most recent short interest data has been released for the 07/13/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
- ORILISSA™ (elagolix) is the first FDA-approved oral treatment for the management of moderate to severe pain associated with endometriosis in over a decade
As cannabis becomes more and more legal, investors have started to wonder what that means for them.
NORTH CHICAGO, Ill., July 17, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today patent license agreements with Mylan over its proposed biosimilar adalimumab product.
The large-cap pharma sector has left investors wanting more, but these three companies could provide some excitement at the end of the second quarter.
- Acute myeloid leukemia (AML) is one of the most aggressive cancers, with a very low survival rate and few options available for patients who are ineligible for intensive chemotherapy - Median survival is five to 10 months in older AML patients who are...
- The ibrutinib clinical program is designed to fully explore the potential of this first-in-class molecule as a single or combination therapy for multiple cancers and other diseases.
NORTH CHICAGO, Ill., July 10, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its second-quarter 2018 financial results on Friday, July 27, 2018, before the market opens.
On the search for promising stocks, give these 10 names from Goldman Sachs a consideration.
The most recent short interest data was recently released for the 06/15/2018 settlement date, and AbbVie Inc is the #146 most shorted of the S&P 500 components, based on 4.35 "days to cover." There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then divided by the average daily volume, to express the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Galapagos' new cystic fibrosis drug trial results were weaker than expected.
Indica and sativa are commonly-known distinctions among cannabis enthusiasts. But is there actually a distinct difference between the two? What roles do cannabinoids and terpenes play?
- Extension builds on collaboration established in 2014
- The filing is based on data from the Phase 3 iNNOVATE study, which suggest that IMBRUVICA plus rituximab may improve outcomes across all lines of Waldenström's macroglobulinemia (WM) treatment, including patients with prior lines of therapy and various genetic factors, versus rituximab alone
- Collaboration will focus on switchable CAR-T therapies aimed primarily at solid tumors
The Civic 50 recognizes AbbVie as one of the most community-minded companies in the U.S.
- 83 percent (n=100) of 121 patients who achieved undetectable minimal residual disease (uMRD) at the end of combination therapy with VenR (n=194), maintained uMRD and were progression-free at 13.8 months of follow-up
NORTH CHICAGO, Ill., June 14, 2018 /PRNewswire/ -- The board of directors of AbbVie Inc.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.